Susquehanna International Group, LLP Tcr2 Therapeutics Inc. Call Options Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	SELL	$0.83 - $1.44 $19,422 - $33,696	-23,400 Reduced 26.47%	65,000 $65,000
Q3 2022 Nov 14, 2022	BUY	$1.86 - $3.75 $44,082 - $88,875	23,700 Added 36.63%	88,400 $159,000
Q2 2022 Aug 15, 2022	BUY	$2.11 - $2.94 $47,475 - $66,150	22,500 Added 53.32%	64,700 $188,000
Q3 2021 Nov 15, 2021	BUY	$8.44 - $18.35 $261,639 - $568,850	31,000 Added 276.79%	42,200 $359,000
Q2 2021 Aug 11, 2021	SELL	$16.41 - $24.71 $49,230 - $74,130	-3,000 Reduced 21.13%	11,200 $184,000
Q1 2021 May 17, 2021	SELL	$20.38 - $34.07 $853,922 - $1.43 Million	-41,900 Reduced 74.69%	14,200 $314,000
Q4 2020 Feb 16, 2021	BUY	$19.0 - $32.63 $418,000 - $717,860	22,000 Added 64.52%	56,100 $1.74 Million
Q3 2020 Nov 16, 2020	BUY	$13.1 - $20.69 $446,710 - $705,529	34,100 New	34,100 $693,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.